Artificial intelligence is reshaping how new medicines are found, collapsing a process that once took years into a matter of weeks, according to a report from 24/7 Wall St.
The stakes are enormous. Bringing a drug to market traditionally runs on a 10-to-15-year pipeline, and roughly 90% of candidates never reach approval, the report notes. That long timeline and high failure rate make drug development one of the most expensive and risky pursuits in business — which is exactly why faster, cheaper screening of potential candidates is so valuable.
The report frames AI-driven drug discovery as the "next trillion-dollar biotech opportunity," pointing to the scale of the prizes on offer. As one marker of how lucrative a single successful drug can be, it cites Eli Lilly's tirzepatide franchise, which it says generated $36.5 billion.
The core idea is straightforward: if AI can help researchers identify promising compounds and weed out likely failures earlier, companies could spend less time and money chasing dead ends. Shaving years off the front end of the pipeline would not only cut costs but could get treatments to patients sooner.
The sources here are market-focused commentary rather than peer-reviewed clinical results, so the specific timelines and projections reflect industry optimism more than settled outcomes.
Why it matters: if AI can reliably shorten a drug-development cycle that today runs over a decade with a 90% failure rate, it could lower the cost of new medicines and reshape one of the economy's largest and most consequential industries.